Brief: Cyclo Therapeutics Submits Investigational New Drug Application To U.S. FDA
16/11/2021 13:20
Nov 16 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG
APPLICATION
TO U.S. FDA TO ADVANCE TRAPPSOL® CYCLO™ IN PHASE 2 STUDY FOR
TREATMENT OF ALZHEIMER’S DISEASE
Source text for Eikon: ID:nBw2J1Kbpa
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug